APSR2026-457

 
Late-Breaking
Submitted
Poster Presentation
 
AP14-045
P64
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1220569-46904-Managing metachronous malignancies- Advanced lung adenocarcinoma in a patient with chronic myeloid leukemia on imatinib Poster_434303.pd
Format: PDF Only
08. Lung Cancer
4

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Jeffrey Yong Ye Tan * Hospital Tuanku Ja'afar Respiratory Unit, Department of Internal Medicine Seremban Malaysia
Anez Aslan - Hospital Tuanku Ja'afar Respiratory Unit, Department of Internal Medicine Seremban Malaysia
Han Loong Tan - Hospital Tuanku Ja'afar Respiratory Unit, Department of Internal Medicine Seremban Malaysia
Raymund Dass Maria Dass - Hospital Tuanku Ja'afar Respiratory Unit, Department of Internal Medicine Seremban Malaysia
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Jeffrey Yong Ye
Tan
jeffrey602162@gmail.com
+60126333855
Under 30
Malaysia
Case Report
Managing metachronous malignancies: advanced lung adenocarcinoma in a patient with chronic myeloid leukemia on imatinib
Maximum 25 words
Abstract Content
 
 
 
 
Metachronous malignancies are becoming increasingly common especially in certain malignancies with better long-term survival rates. Chronic myeloid leukemia (CML) outcomes have improved with the introduction of tyrosine kinase inhibitors (TKIs), leading to near-normal life expectancy for many patients. However, this extended survival has brought increasing recognition of secondary malignancies.
We report a case of a 61-year-old Malay gentleman with chronic myeloid leukemia (CML) in chronic phase who had achieved partial molecular response with tyrosine kinase inhibitors, imatinib for 3 years, and subsequently diagnosed with advanced lung adenocarcinoma. He was diagnosed with chronic myeloid leukemia in chronic phase at 59-year-old and was started on tyrosine kinase inhibitor therapy with imatinib. BCR-ABL p210 quantification at baseline was 4.28%, which decreased to 0.33% after three years of imatinib therapy. However, he developed worsening shortness of breath and significant weight loss over two months. Initial clinical examination revealed massive left pleural effusion with left supraclavicular lymphadenopathy. Diagnostic thoracocentesis revealed an exudative effusion, and he subsequently underwent CT thorax, which showed massive left pleural effusion with right lung nodules, mediastinal and left supraclavicular lymphadenopathy. A suspicious hypodense lesion in the right lobe of the liver was also noted. Pleuroscopy was then performed and the parietal pleural biopsy revealed metastatic adenocarcinoma with EGFR mutation not detected. He was commenced on systemic chemotherapy and tyrosine kinase inhibitor therapy was withheld temporarily due to potential risk of drug-drug interaction. At present, he is in his third cycle of chemotherapy and is responding well. Further imaging is planned to assess chemotherapy response.
This case highlights the therapeutic dilemma of continuing or withholding TKI during systemic chemotherapy. Concerns regarding drug-drug interaction and overlapping toxicities influence clinical decision making. Nonetheless this case underscores the diagnostic vigilance of metachronous malignancy in long-term CML survivors.
 
 
No
No
 
JPG or JPEG or PNG format ONLY
metachronous malignancy, lung adenocarcimona, tyrosine-kinase inhibitors
maximum 3 keywords and no abbreviations, separated by commas
 
294